MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,000,000 shares of common stock to 3,582,000 shares of common stock sold by the company. The shares are being offered to the public at a price of $25.00 per share, resulting in aggregate proceeds of approximately $89.6 million before underwriting discounts and expenses. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 537,300 shares of common stock from the company.
J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Leerink Partners, Canaccord Genuity and William Blair are acting as co-managers.
The registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2015. Copies of the effective registration statement, as amended, can be accessed through the SEC's website at www.sec.gov. The offering of these securities will be made only by means of a prospectus, copies of which, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by e-mail at prospectus-eq_fi@jpmchase.com, or by telephone at (866) 803-9204, or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, or by e-mail at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections and is one of the most costly conditions to U.S. employers.
XENT-F
